AXON is pulling back from its post-earnings highs with short sellers quietly adding exposure — yet the borrow market remains far too loose to suggest a squeeze is anywhere near.
The headline tension this week is a stock down 3.8% over seven days, trading at $435.39, after a month that delivered an 11% gain on the back of a blowout earnings print. That gap — a strong fundamental narrative meeting renewed short-side interest — defines the setup heading into August results.
Short interest has been grinding higher, and the pace matters here. SI has climbed roughly 15% over the past month to 5.0% of the free float, with the week-on-week move adding another 3.7%. That brings estimated short shares to just under four million. The rebuild is notable: the May earnings report sent the stock up more than 14% the day after, and 31% over the following five days, but shorts have been replenishing positions ever since. Yet the borrow market offers no squeeze pressure. Availability is running above 550% — meaning roughly five-and-a-half shares are available to lend for every one already borrowed — and cost to borrow is a minimal 0.52%, barely changed on the week. The lending pool is wide open. Options positioning adds a slightly different shade: the put/call ratio has eased to 1.02, actually below its 20-day average of 1.06 and tracking near its 52-week low of 0.90. Call activity has picked up relative to puts, suggesting some options participants are leaning into the dip rather than hedging against further downside.
The Street remains largely constructive, but the conviction gap between bulls and the stock price is significant. The mean analyst price target, last compiled around the May earnings print, sits near $662 — implying over 50% upside from current levels. Most firms that moved post-earnings kept Overweight or Buy ratings while trimming numbers: JP Morgan lifted its target modestly to $755, while Barclays and several others cut theirs, with UBS holding Neutral at $440. The clustering of bull targets in the $650-$825 range versus a stock at $435 reflects confidence in the long-term ecosystem story — AI-enhanced public safety, next-gen 911, healthcare adjacencies — but also acknowledgement that the valuation de-rating since early 2026 has been real. The trailing PE runs near 48x and EV/EBITDA near 32x, both down on the week, while the company's EPS surprise factor ranks in the 79th percentile, confirming a strong execution track record even as the multiple has compressed. Bears, meanwhile, flag cost sensitivity among law enforcement buyers and uncertainty about whether Axon's pricing model can sustain margins as it pushes into new verticals.
One ownership angle worth noting: company founder and long-term holder Patrick Smith reported a net increase of roughly 271,000 shares through early June, a meaningful add at a significant dollar outlay. Against that, President Joshua Isner sold approximately $2.7 million across multiple tranches on June 5 — small relative to his holding but the kind of systematic selling that tends to reflect scheduled plans rather than a read on near-term direction.
The May and Q1 earnings history underscores how explosive this stock can be around results. The last print produced a 14.7% single-day move and a five-day follow-through of 31%. The next event is scheduled for August 4. Between now and then, the watch is whether the short rebuild continues to accelerate — and whether that borrow availability starts to tighten meaningfully — or whether the dip attracts fresh long demand that forces covers before results arrive.
See the live data behind this article on ORTEX.
Open AXON on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
